Healthcare / Medical DevicesJakartaID
$140.00
+2.00 (+1.45%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-20.5B · quality 56.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$553.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
8.9%
↑Gross Margin
33.8%
↓Debt/Equity
0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
+11.3%
FCF CAGR
—
FCF margin
4.4%
FCF / Net income
0.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $199.30B · net income $13.51B · FCF $8.68B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $199.30B | $199.30B | $147.64B | $136.70B | $93.29B | $129.96B |
| Net Income | $13.51B | $13.51B | $2.95B | $2.19B | $2.83B | $308.3M |
| EBITDA | $34.53B | $34.53B | $21.96B | $17.94B | $14.87B | $10.61B |
| EPS | 2.29 | 2.29 | 0.75 | 0.55 | 0.72 | 0.08 |
| Gross Margin | 33.8% | 33.8% | 30.9% | 34.0% | 32.4% | 40.9% |
| Operating Margin | 10.2% | 10.2% | 6.1% | 4.3% | 3.6% | 2.5% |
| Net Margin | 6.8% | 6.8% | 2.0% | 1.6% | 3.0% | 0.2% |
| Balance Sheet | ||||||
| Debt/Equity | 0.18 | 0.18 | 0.26 | 0.84 | 0.42 | 3.38 |
| Current Ratio | 2.52 | 2.52 | 3.02 | 1.23 | 0.99 | 0.70 |
| Cash Flow | ||||||
| Free Cash Flow | $8.68B | $8.68B | $-20.49B | $-34.95B | $-18.94B | $-32.34B |
| Returns | ||||||
| ROE | 8.9% | 8.9% | 2.1% | 4.4% | 6.0% | 3.3% |
| Growth & Yield | ||||||
| Revenue Growth | 35.0% | 35.0% | 8.0% | 46.5% | -28.2% | — |
| EPS Growth | 206.0% | 206.0% | 34.8% | -22.7% | 819.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
75.8%
EPS terminal req.
$12.42
Spread vs growth
130.2%
5Y implied EPS CAGR
45.7%
EPS terminal req.
$15.03
Spread vs growth
160.2%
10Y implied EPS CAGR
26.6%
EPS terminal req.
$24.21
Spread vs growth
179.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+6.9%
Start / end P/E
175.3x → 61.2x
EPS bridge
0.75 → 2.29
Residual
-134.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.